Predicting survival times for neuroblastoma patients using RNA-Seq expression profiles

Author

Tyler Grimes

Published

July 23, 2017

My talk at the ISMB/CAMDA International Conference in Chicago, IL.

Abstract

Gene expression profiles from RNA-sequencing provide a window to the activity inside tumor cells. This view has enabled researchers to identify driver genes for the pathology, but often these results fail to validate or only hold for the particular cancer at hand. In this study, we investigate a robust method for identifying cancer-related genes. Two criteria are used: a gene must show functional changes among clinically different groups of patients, and the gene must have clinical relevance. These conditions are assessed through a differential network analysis and by modelling patient survival times. Preliminary results are shown from a neuroblastoma and breast cancer dataset.

Event: ISMB/CAMDA 2017, Prague, Czech Republic

Slides

Q&A starts at 16:20

Back to top